Initiating dopaminergic treatment in Parkinson's disease-Reference-Cited by-同舟云学术

Initiating dopaminergic treatment in Parkinson's disease

Published:2014-09 Issue:9949 Volume:384 Page:1164-1166
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Lang Anthony E,Marras Connie

Publisher

Elsevier BV

Subject

General Medicine

Reference14 articles.

1. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial;Lancet,2014

2. “Levodopa phobia”: A new iatrogenic cause of disability in Parkinson disease;Kurlan;Neurology,2005

3. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it;Fahn;Ann Neurol,1992

4. Young onset Parkinson's disease;Quinn;Mov Disord,1987

5. Pharmacological treatment of Parkinson disease: a review;Connolly;JAMA,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemical library design, QSAR modeling and molecular dynamics simulations of naturally occurring coumarins as dual inhibitors of MAO-B and AChE;Journal of Biomolecular Structure and Dynamics;2023-05-18

2. Introduction of benzyloxy pharmacophore into aryl/heteroaryl chalcone motifs as a new class of monoamine oxidase B inhibitors;Scientific Reports;2022-12-27

3. Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors;Pharmaceuticals;2022-09-16

4. Estimates of Intracellular Dopamine in Parkinson’s Disease: A Systematic Review and Meta-Analysis;Journal of Parkinson's Disease;2021-08-02

5. Nanomedicine against Alzheimer’s and Parkinson’s Disease;Current Pharmaceutical Design;2021-04